Home > Dermatology > One week enough to clear pustular psoriasis in half of patients after experimental infusion

One week enough to clear pustular psoriasis in half of patients after experimental infusion


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters Health - 22/12/2021 - A single intravenous infusion of Boehringer Ingelheim's experimental treatment for pustular psoriasis can dramatically reduce the number of lesions after only one week, according to results of a phase-2 trial. But the interleukin-36-receptor inhibitor spesolimab may have sparked infections in up to 47% of volunteers over 12 weeks and antidrug antibodies were detected in nearly half of patients, researchers report in the New England Journal of Medicine. "To put this into perspective, these are non-life-threatening infections that don't contribute to the demise of patients at all," versus a condition that can lead to deadly infections, senior author Dr. Mark Lebwohl of the Icahn School of Medicine at Mount Sinai, in New York City, told Reuters Health by phone. "There's really no contest there." Pustular psoriasis is the rarest form of psoriasis, afflicting roughly one in 12,500 people worldwide. The autoinflammatory skin disease, w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on